Research: FTC Substantiation Guidelines

Summary

This document outlines the regulatory standards enforced by the Federal Trade Commission (ftc) regarding the advertising and marketing of health-related products, dietary supplements, and functional foods. It details the jurisdictional divide between the fda (which handles product safety and labeling, including gras-generally-recognized-as-safe) and the FTC (which handles all advertising and marketing materials).

The core legal threshold for health and wellness claims is competent-and-reliable-scientific-evidence, which generally requires well-designed, randomized, controlled human clinical trials (RCTs). The FTC emphasizes that study results must not only be statistically significant but also clinically meaningful to consumers.

Key Findings

• Strict Substantiation is Mandatory: The FTC requires a “reasonable basis” for all express and implied marketing claims. For health and wellness beverages, this usually means high-quality RCTs.
• The “Clinically Proven” Trap: Using definitive language like “clinically proven” without a perfectly aligned, highly powered RCT is a “litigation magnet.” The document cites the supplement brand prevagen as a cautionary example of a brand facing enforcement actions and civil litigation for such claims.
• Clinical Meaningfulness Over Statistical Significance: The FTC requires that the benefits touted in marketing are actually noticeable and meaningful to the consumer, not just mathematically significant in a lab setting.
• Jurisdictional Divide: While the FDA controls safety and the physical label, the FTC controls all advertising (digital, influencer, print). The ttb may also assert oversight for non-alcoholic products produced by traditional alcohol companies, creating a complex compliance web.
• Impact on Functional Beverages: Brands utilizing adaptogens (like kin-euphorics and curious-elixirs) must strictly adhere to these guidelines, navigating the boundary of structure-function-vs-drug-claims and the beverage-vs-supplement-ambiguity. A major vulnerability is the clinical-substantiation-gap, as there is a lack of well-powered RCTs proving the efficacy of adaptogens specifically in beverage-sized doses.

Strategic Implications for Asahi

If Asahi pursues a multi-beverage strategy incorporating mood-altering ingredients, it cannot rely on generic historical ingredient data. It must fund format-specific RCTs to avoid FTC penalties and class-action lawsuits, especially if marketing in the US.